These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7603198)

  • 21. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE inhibition and renovascular disease.
    Carr S
    Diabet Med; 2001 Jan; 18 Suppl 1():4-6. PubMed ID: 11289190
    [No Abstract]   [Full Text] [Related]  

  • 23. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
    Jacobsen P; Rossing K; Rossing P; Tarnow L; Mallet C; Poirier O; Cambien F; Parving HH
    Kidney Int; 1998 Apr; 53(4):1002-6. PubMed ID: 9551410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACE inhibitors and hypoglycaemia.
    Kong N; Bates A; Ryder RE
    Lancet; 1995 Jul; 346(8967):125; author reply 126-7. PubMed ID: 7677857
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
    Kageyama S
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):180-1. PubMed ID: 18421844
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
    Elliott HL
    Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ACE inhibition on the course of nephropathy in type I diabetes mellitus.
    Meinders AE; Hes R; de Leeuw PW
    Neth J Med; 1992 Jun; 40(5-6):217-20. PubMed ID: 1436257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
    Mazerska M; Myśliwiec M
    Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy.
    Imanishi M; Yoshioka K; Okumura M; Konishi Y; Tanaka S; Fujii S; Kimura G
    Kidney Int Suppl; 1997 Dec; 63():S198-200. PubMed ID: 9407458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACE-inhibitors in severe hypertension.
    Herlitz H
    Scand J Urol Nephrol Suppl; 1984; 79():73-9. PubMed ID: 6089321
    [No Abstract]   [Full Text] [Related]  

  • 31. [Protective effect of antihypertensive agents on renal insufficiency (REIN, RENAAL, IDNT, AASK, etc)].
    Tsuchida H; Kimura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():617-22. PubMed ID: 15171445
    [No Abstract]   [Full Text] [Related]  

  • 32. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diabetic nephropathy: current diagnostics and treatment].
    Werth S; Lehnert H; Steinhoff J
    Internist (Berl); 2015 May; 56(5):513-9. PubMed ID: 25762007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy.
    Hovind P; Tarnow L; Rossing P; Carstensen B; Parving HH
    Kidney Int; 2004 Sep; 66(3):1180-6. PubMed ID: 15327415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Who is tested for diabetic kidney disease and who initiates treatment? The Translating Research Into Action For Diabetes (TRIAD) Study.
    Johnson SL; Tierney EF; Onyemere KU; Tseng CW; Safford MM; Karter AJ; Ferrara A; Duru OK; Brown AF; Narayan KM; Thompson TJ; Herman WH
    Diabetes Care; 2006 Aug; 29(8):1733-8. PubMed ID: 16873772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renal side effects of angiotensin converting enzyme inhibitors].
    Schmidt A; Mayer G
    Wien Med Wochenschr; 1996; 146(16):454-6. PubMed ID: 9036683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preserving the diabetic kidney.
    Poirier SJ
    J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
    Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
    Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Renal histopathology of diabetic nephropathy].
    Suzuki Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():314-9. PubMed ID: 15999726
    [No Abstract]   [Full Text] [Related]  

  • 40. Angiotensin converting enzyme inhibitors in perspective: an update.
    Burrell LM; Johnston CI
    Aust Fam Physician; 1993 Jul; 22(7):1243-7, 1251, 1255. PubMed ID: 8373316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.